![Gregory Conn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 108 882 $ in data 30/06/2026
Gregory L.
Conn is the founder of PDS Operating Corp.
Dr. Conn is Chief Scientific Officer at PDS Biotechnology Corp.
since 2005.
Dr. Conn was Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn completed graduate and doctorate degrees at Albert Einstein College of Medicine, Inc.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 12/01/2026 | 123.589 ( 0,22% ) | 108 882 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/01/2005 |
| Società | Posizione | Fine |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2000 |
PDS Operating Corp.
 PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Fondatore | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDS Biotechnology Corp.
 PDS Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Develops clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
